Though H.C.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares tumbled nearly 11% in Wednesday’s trading session, as Wall Street came down hard on the drug maker. …
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is scheduled to report its fourth-quarter earnings tomorrow morning, and H.C.
Chief scientist Shaw looks for unusual sources of return in MNKD and VRX.
Fears about financial control should be a buying opportunity in Valeant stock, says Cantor.
Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) Ortho Dermatologics division announced results from the Pivotal Phase 3 long-term extension study (AMAGINE-2), which demonstrated that SILIQ™ (brodalumab) …
TEVA needs a long-term solution after MYL’s generic Copaxone approval; VRX works on its debt problem.
Valeant’s comeback progresses with new notes offering; RedHill ups the risk ante in favor of time/money.
Bausch + Lomb, a division of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), announced the introduction of Biotrue® ONEday for Astigmatism daily disposable contact lenses in 20 …
A glimpse into why Louise Chen believes Valeant is the better biotech play than Teva down the line.
